DeepMed Research

Janssen Scientific Affairs, LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study to Assess the Engagement and Usefulness of Care4Today Digital Platform for Disease Management in Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD) Population

Completed

Conditions: Coronary Artery Disease (CAD)
Peripheral Artery Disease (PAD)

Interventions: Device: Care4Today® Connect CAD-PAD Mobile Application

First Posted Date: 2023-09-25

Last Posted Date: 2025-04-27

Lead Sponsor: Janssen Scientific Affairs, LLC

Target Recruit Count: 277

Registration Number: NCT06052319

Locations: 🇺🇸
University of Florida Health Jacksonville, Jacksonville, Florida, United States
🇺🇸
University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
🇺🇸
Rio Grande Regional Hospital, McAllen, Texas, United States

and more 3 locations

A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Cilta-cel
Drug: Lymphodepleting Therapy (Cyclophosphamide and Fludarabine)

First Posted Date: 2022-04-26

Last Posted Date: 2025-04-25

Lead Sponsor: Janssen Scientific Affairs, LLC

Target Recruit Count: 86

Registration Number: NCT05347485

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Washington University School Of Medicine, Saint Louis, Missouri, United States
🇺🇸
City of Hope, Duarte, California, United States

and more 15 locations

Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-Cel) Out-of-Specification (OOS) in Participants With Multiple Myeloma

Conditions: Multiple Myeloma

First Posted Date: 2022-04-26

Last Posted Date: 2025-04-25

Lead Sponsor: Janssen Scientific Affairs, LLC

Registration Number: NCT05346835

A Study of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Evaluated as a Fixed Dose Combination Regimen in Participants Switching From an Integrase Inhibitor Who Have Experienced Rapid Weight Gain

Phase 4

Completed

Conditions: HIV-1

Interventions: Drug: D/C/F/TAF FDC
Drug: TAF/FTC FDC
Drug: INI Based Regimen

First Posted Date: 2020-06-23

Last Posted Date: 2025-03-30

Lead Sponsor: Janssen Scientific Affairs, LLC

Target Recruit Count: 103

Registration Number: NCT04442737

Locations: 🇺🇸
Triple O Research Institute, West Palm Beach, Florida, United States
🇺🇸
Midway Immunology and Research Center, Fort Pierce, Florida, United States
🇺🇸
Medical College of Georgia, Augusta, Georgia, United States

and more 31 locations

A Study to Assess the Long-Term Safety of Ustekinumab Versus Other Biologics in Patients With Crohn's Disease and Ulcerative Colitis

Recruiting

Conditions: Crohn Disease
Colitis, Ulcerative

Interventions: Drug: Ustekinumab
Drug: Other Biologic Therapies

First Posted Date: 2020-05-01

Last Posted Date: 2025-04-06

Lead Sponsor: Janssen Scientific Affairs, LLC

Target Recruit Count: 1056

Registration Number: NCT04372108

Locations: 🇺🇸
NMCP, Portsmouth, Virginia, United States

A Study to Investigate if Early Atrial Fibrillation (AF) Diagnosis Reduces Risk of Events Like Stroke in the Real-World

Completed

Conditions: Atrial Fibrillation

Interventions: Device: Heart healthy Engagement Program with the Apple Watch Series 5 or later
Device: Anti-Coagulation Adherence Module with the Apple Watch Series 5 or later

First Posted Date: 2020-02-19

Last Posted Date: 2025-04-25

Lead Sponsor: Janssen Scientific Affairs, LLC

Target Recruit Count: 34244

Registration Number: NCT04276441

Locations: 🇺🇸
Evidation Health, San Mateo, California, United States

Expanded Access Program (EAP) for Participants With Advanced Cancers and Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations Who Have Exhausted All Treatment Options

Conditions: Advanced Cancers and FGFR Genetic Alterations

First Posted Date: 2019-01-31

Last Posted Date: 2019-05-13

Lead Sponsor: Janssen Scientific Affairs, LLC

Registration Number: NCT03825484

Sustainable Early Episode Clinic Study (SEEC)

Not Applicable

Completed

Conditions: Schizoaffective Disorder
Schizophrenia

Interventions: Behavioral: Sustainable Early Episode Clinic Model of Care

First Posted Date: 2018-06-27

Last Posted Date: 2025-04-27

Lead Sponsor: Janssen Scientific Affairs, LLC

Target Recruit Count: 50

Registration Number: NCT03571685

Locations: 🇺🇸
Sharp Outpatient Behavioral Health Clinic, San Diego, California, United States

Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year

Phase 3

Completed

Conditions: Crohn Disease

Interventions: Biological: Placebo for Adalimumab
Biological: Placebo for Ustekinumab
Biological: Ustekinumab (6 mg/kg)
Biological: Adalimumab (40 mg)
Biological: Ustekinumab (90 mg)

First Posted Date: 2018-03-13

Last Posted Date: 2025-04-29

Lead Sponsor: Janssen Scientific Affairs, LLC

Target Recruit Count: 386

Registration Number: NCT03464136

Locations: 🇧🇬
2-nd MHAT, Sofia, Bulgaria
🇨🇦
CISSS de la Monteregie Centre, Greenfield Park, Quebec, Canada
🇨🇦
CMIIM, Centre médical L'Enjeu, Mont-Royal, Quebec, Canada

and more 177 locations

A Study to Quantify Use of Anticoagulation to Improve Management of Atrial Fibrillation

Terminated

Conditions: Atrial Fibrillation

First Posted Date: 2017-12-26

Last Posted Date: 2019-12-26

Lead Sponsor: Janssen Scientific Affairs, LLC

Target Recruit Count: 2000

Registration Number: NCT03382613

Locations: 🇺🇸
Banner Baywood Medical Center, Mesa, Arizona, United States
🇺🇸
St. Agnes Hospital, Baltimore, Maryland, United States
🇺🇸
Geisinger Wyoming Valley, Wilkes-Barre, Pennsylvania, United States

and more 58 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy